Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction

[1]  J. Cohn,et al.  Effect of Baseline and Changes in Systolic Blood Pressure Over Time on the Effectiveness of Valsartan in the Valsartan Heart Failure Trial , 2008, Circulation. Heart failure.

[2]  B. Pitt,et al.  ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). , 1995, European heart journal.

[3]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[4]  S. Oparil,et al.  Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. , 1998, The American journal of cardiology.

[5]  S. Solomon,et al.  Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction , 2018, American journal of hypertension.

[6]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[7]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[8]  S. Oparil,et al.  Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. , 1998, The American journal of cardiology.

[9]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[10]  J. McMurray,et al.  Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS‐HF) , 2010, European journal of heart failure.

[11]  K. Lindmark,et al.  Obstacles to mineralocorticoid receptor antagonists in a community‐based heart failure population , 2018, Cardiovascular therapeutics.

[12]  P. Ponikowski,et al.  Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT‐CHF , 2017, European journal of heart failure.

[13]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[14]  A. Cohen-Solal,et al.  Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. , 2008, European heart journal.

[15]  K. Swedberg,et al.  Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT , 2014, European journal of heart failure.

[16]  J. Rouleau,et al.  Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. , 2004, Journal of the American College of Cardiology.

[17]  J. McMurray,et al.  Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations , 2012, Circulation.

[18]  K. Swedberg,et al.  Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. , 2013, American heart journal.

[19]  H. Dargie,et al.  The Cardiac Insufficiency Bisoprolol Study II , 1999, The Lancet.

[20]  S. Solomon,et al.  Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF , 2017, European heart journal.

[21]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[22]  L. Lund,et al.  Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry , 2018, European journal of heart failure.

[23]  S. Solomon,et al.  Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. , 2008, Journal of the American College of Cardiology.

[24]  P. Ponikowski,et al.  Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure , 2013, Heart Failure Reviews.

[25]  Isla Mackenzie,et al.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial , 2015, The Lancet.

[26]  J. McMurray,et al.  Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). , 2013, Journal of the American College of Cardiology.